Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic

摘要

To the Editor: Diabetes represents a pandemic that has been recognized as an independent risk factor for severe infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the context of the coronavirus disease 19 (COVID-19) pandemic, although it may not actually increase the risk for SARS-CoV-2 transmission for patients with diabetes compared with the general population. Patients with diabetes feature a twofold increase in the odds for severe SARS-CoV-2 infection and a two- to threefold increase in the odds for death because of disease. Patients with diabetes experience a significant increase in the risk for in-hospital death because of SARS-CoV-2 infection, as shown in a recent, large nationwide study. Therefore, optimal treatment strategy for these patients becomes a top priority.